SL
BIB icon

Savior LLC’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Savior LLC’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-8
Closed -$462 – 176
2022
Q4 		$462 Sell
8
-1
-11% -$56 ﹤0.01% 164
2022
Q3 		$0 Hold
9
– – ﹤0.01% 193
2022
Q2 		$0 Buy
9
+2
+29% +$102 ﹤0.01% 165
2022
Q1 		$0 Buy
7
+1
+17% +$61 ﹤0.01% 163
2021
Q4 		$0 Hold
6
– – ﹤0.01% 180
2021
Q3 		$1K Hold
6
– – ﹤0.01% 166
2021
Q2 		$1K Sell
6
-1
-14% -$87 ﹤0.01% 776
2021
Q1 		$1K Sell
7
-2
-22% -$189 ﹤0.01% 802
2020
Q4 		$1K Sell
9
-2
-18% -$155 ﹤0.01% 771
2020
Q3 		$1K Buy
11
+1
+10% +$71 ﹤0.01% 735
2020
Q2 		$1K Buy
+10
New +$639 ﹤0.01% 700

Other funds holding BIB

IMC Chicago
IMC Chicago Chicago, Illinois $278B AUM 44.93% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
CCWM
Cassaday & Co Wealth Management Mclean, Virginia $4.69B AUM 20.56% 1-Year Est. Return
CIC
Chase Investment Counsel Charlottesville, Virginia $381M AUM 69.8% 1-Year Est. Return
CIA
Capital Investment Advisors Atlanta, Georgia $6.84B AUM 17.28% 1-Year Est. Return
JF
Jump Financial Chicago, Illinois $7.5B AUM 33.9% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Savior LLC's BIB Position: Q1 2023 in Review

Savior LLC sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q1 2023, closing a stake of 8 shares — an estimated $462 sold.

Savior LLC first reported a position in BIB in Q2 2020 and held it in 11 quarters. The position peaked at $1K in Q3 2021. 24 funds tracked by Wall St. Rank hold BIB as of Q1 2023.

  • Savior LLC reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q1 2023 after selling out during the quarter.
  • Savior LLC sold 8 ProShares Ultra NASDAQ Biotechnology shares in Q1 2023, an estimated $462.
  • Savior LLC first reported a position in ProShares Ultra NASDAQ Biotechnology in Q2 2020 and held it in 11 quarters.
  • Savior LLC's ProShares Ultra NASDAQ Biotechnology position peaked at $1K in Q3 2021.
  • 24 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q1 2023.

Based on Savior LLC's 13F filing for Q1 2023, filed 6 Apr 2023.